49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03562065 (ClinicalTrials.gov) | September 11, 2019 | 22/5/2018 | Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord | Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord | Lupus Erythematosus;Stem Cell Transplant | Biological: mesenchymal stem cells | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | 70 Years | All | 10 | Phase 1/Phase 2 | France |
| 2 | NCT04184258 (ClinicalTrials.gov) | July 1, 2019 | 1/12/2019 | Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells | Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells | Systemic Lupus Erythematosus | Biological: Pooled mesenchymal stem cell;Other: Standard treatment according to the Clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Completed | 18 Years | 75 Years | All | 7 | Phase 1/Phase 2 | Belarus |
| 3 | NCT02633163 (ClinicalTrials.gov) | October 26, 2018 | 15/12/2015 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus | Systemic Lupus Erythematosus | Drug: Low Dose Mesenchymal Stem Cells (MSCs);Drug: High Dose Mesenchymal Stem Cells (MSCs);Drug: Placebo Infusion | Medical University of South Carolina | NULL | Recruiting | 18 Years | 65 Years | All | 81 | Phase 2 | United States |
| 4 | EUCTR2017-001400-29-FR (EUCTR) | 16/03/2018 | 31/07/2018 | Treatment of systemic lupus erythematosus by injection iv of mesenchymal stem cells (MSC-LES) | Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE - MSC-LES | Treatment of Systemic Lupus Erythematosus refractory to standard treatments. MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD Product Code: 0 INN or Proposed INN: 0 Other descriptive name: CSM allogéniques issues de cordons ombilicaux ( MTI-PP) | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 10 | Phase 1;Phase 2 | France | ||
| 5 | NCT03219801 (ClinicalTrials.gov) | August 1, 2017 | 10/7/2017 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus | Evaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells | Systemic Lupus Erythematosus | Biological: mesenchymal stem cells | Hebei Medical University | NULL | Not yet recruiting | 14 Years | 60 Years | All | 10 | Early Phase 1 | China |
| 6 | NCT03171194 (ClinicalTrials.gov) | April 27, 2017 | 4/5/2017 | Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus | A Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus | System; Lupus Erythematosus | Drug: Low Dose Mesenchymal Stem Cells (MSCs) | Medical University of South Carolina | NULL | Completed | 18 Years | 65 Years | All | 6 | Phase 1 | United States |
| 7 | NCT01741857 (ClinicalTrials.gov) | January 2012 | 26/11/2012 | Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus | Phase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Biological: human umbilical cord derived MSC transplantation for SLE | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | NULL | Recruiting | 15 Years | 60 Years | Both | 40 | Phase 1/Phase 2 | China |
| 8 | NCT00698191 (ClinicalTrials.gov) | March 2007 | 13/6/2008 | Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE) | Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus | Refractory Systemic Lupus Erythematosus | Biological: Allogeneic MSC (AlloMSC) | Nanjing Medical University | National Natural Science Foundation of China | Recruiting | 15 Years | 70 Years | Both | 20 | Phase 1/Phase 2 | China |